

Abstract

Background

Novaferon, a novel protein drug approved for the treatment of chronic hepatitis B in China, exhibits potent antiviral activities. We aimed to determine the anti-SARS-CoV-2 effects of Novaferon in vitro, and conducted a randomized, open-label, parallel group study to explore the antiviral effects of Novaferon for COVID-19.

Methods

In laboratory, the inhibition of Novaferon on viral replication in cells infected with

1. Introduction

2. Methods

based on statistical consideration.

Acknowledgmentsk5-0.k5-0.ktTe0 copyright holder for Weis preprint .4Tj/GS1 gsk

References

- [1] WHO. Coronavirus disease 2019 (COVID-19) Situation Report–76. Accessed April 4, 2020. www.who.int/docs/default-source/coronaviruse/situation-reports/20200405-sitrep-76-covid-19.pdf?sfvrsn=6ecf0977_2

<http://image.thelancet.com/extras/03art4432web.pdf>.

Table 3. Analysis for Time to SARS-CoV-2 Clearance

						p value
Novaferon	LPV/r*+	LPV/	LPV/ r	LPV/ r	Novaferon	
	Novaferon	r	vs.	vs. LPV/ r	vs. LPV/ r	
			Novaferon	+Novaferon	+Novaferon	

